1. Torres, J., et al., Crohn's disease. Lancet, 2017. 389(10080): p. 1741-1755.
2. Ungaro, R., et al., Ulcerative colitis. Lancet, 2017. 389(10080): p. 1756-1770.
3. Park, S.J., W.H. Kim, and J.H. Cheon, Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol, 2014. 20(33): p. 11525-37.
4. Kawaguchi, T., et al., Food antigen-induced immune responses in Crohn's disease patients and experimental colitis mice. J Gastroenterol, 2015. 50(4): p. 394-405.
5. Higuchi, L.M., et al., A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol, 2012. 107(9): p. 1399-406.
6. Silverstein, M.D., et al., Cigarette smoking in Crohn's disease. Am J Gastroenterol, 1989. 84(1): p. 31-3.
7. Sartor, R.B. and G.D. Wu, Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology, 2017. 152(2): p. 327-339.e4.
8. Sun, M., et al., Regulatory immune cells in regulation of intestinal inflammatory response to microbiota. Mucosal Immunol, 2015. 8(5): p. 969-978.
9. Kühn, R., et al., Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 1993. 75(2): p. 263-74.
10. Rath, H.C., Role of commensal bacteria in chronic experimental colitis: lessons from the HLA-B27 transgenic rat. Pathobiology, 2002. 70(3): p. 131-8.
11. Ogura, Y., et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 2001. 411(6837): p. 603-6.
12. Frank, D.N., et al., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A, 2007. 104(34): p. 13780-5.
13. Peterson, D.A., et al., Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe, 2008. 3(6): p. 417-27.
14. Nagalingam, N.A. and S.V. Lynch, Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis, 2012. 18(5): p. 968-84.
15. Sheehan, D., C. Moran, and F. Shanahan, The microbiota in inflammatory bowel disease. J Gastroenterol, 2015. 50(5): p. 495-507.
16. Walker, A.W., et al., High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol, 2011. 11: p. 7.
17. Manichanh, C., et al., Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut, 2006. 55(2): p. 205-11.
18. Dorn, I., et al., Lamina propria plasma cells in inflammatory bowel disease: intracellular detection of immunoglobulins using flow cytometry. Immunobiology, 2002. 206(5): p. 546-57.
19. Lin, R., et al., Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease. J Transl Med, 2018. 16(1): p. 359.
20. Rengarajan, S., et al., Dynamic immunoglobulin responses to gut bacteria during inflammatory bowel disease. Gut Microbes, 2020. 11(3): p. 405-420.
21. van der Waaij, L.A., et al., Immunoglobulin coating of faecal bacteria in inflammatory bowel disease. Eur J Gastroenterol Hepatol, 2004. 16(7): p. 669-74.
22. Harmsen, H.J., et al., Crohn's disease patients have more IgG-binding fecal bacteria than controls. Clin Vaccine Immunol, 2012. 19(4): p. 515-21.
23. Lu, L.L., et al., Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol, 2018. 18(1): p. 46-61.
24. Benckert, J., et al., The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific. J Clin Invest, 2011. 121(5): p. 1946-55.
25. Rachmilewitz, D., Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Bmj, 1989. 298(6666): p. 82-6.
26. Best, W.R., et al., Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology, 1976. 70(3): p. 439-44.
27. Bolyen, E., et al., Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol, 2019. 37(8): p. 852-857.
28. Callahan, B.J., et al., DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods, 2016. 13(7): p. 581-3.
29. Singh, S.B., et al., Autophagy Genes of Host Responds to Disruption of Gut Microbial Community by Antibiotics. Dig Dis Sci, 2017. 62(6): p. 1486-1497.
30. Bokulich, N.A., et al., Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. Microbiome, 2018. 6(1): p. 90.
31. Shannon, C.E., The mathematical theory of communication. 1963. MD Comput, 1997. 14(4): p. 306-17.
32. Nishida, A., et al., Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol, 2018. 11(1): p. 1-10.
33. Wallace, K.L., et al., Immunopathology of inflammatory bowel disease. World J Gastroenterol, 2014. 20(1): p. 6-21.
34. Cario, E. and D.K. Podolsky, Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun, 2000. 68(12): p. 7010-7.
35. Palm, N.W., et al., Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell, 2014. 158(5): p. 1000-1010.
36. Brandtzaeg, P., E.S. Baekkevold, and H.C. Morton, From B to A the mucosal way. Nat Immunol, 2001. 2(12): p. 1093-4.
37. Kett, K. and P. Brandtzaeg, Local IgA subclass alterations in ulcerative colitis and Crohn's disease of the colon. Gut, 1987. 28(8): p. 1013-21.
38. Woof, J.M. and M.W. Russell, Structure and function relationships in IgA. Mucosal Immunol, 2011. 4(6): p. 590-7.
39. Ehrenstein, M.R. and C.A. Notley, The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol, 2010. 10(11): p. 778-86.
40. Fadlallah, J., et al., Microbial ecology perturbation in human IgA deficiency. Sci Transl Med, 2018. 10(439).
41. Catanzaro, J.R., et al., IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM. Sci Rep, 2019. 9(1): p. 13574.
42. Rosekrans, P.C., et al., Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study. Gut, 1980. 21(11): p. 941-7.
43. Scott, B.B., et al., Rectal mucosal plasma cells in inflammatory bowel disease. Gut, 1983. 24(6): p. 519-24.
44. Uo, M., et al., Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14 macrophage activation. Gut, 2013. 62(12): p. 1734-44.
45. Preisker, S., et al., Crohn's Disease Patients in Remission Display an Enhanced Intestinal IgM⁺ B Cell Count in Concert with a Strong Activation of the Intestinal Complement System. Cells, 2019. 8(1).
46. Scott, M.G., et al., Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls. Clin Exp Immunol, 1986. 66(1): p. 209-15.
47. Vidarsson, G., G. Dekkers, and T. Rispens, IgG subclasses and allotypes: from structure to effector functions. Front Immunol, 2014. 5: p. 520.
48. Michielan, A. and R. D'Incà, Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. Mediators Inflamm, 2015. 2015: p. 628157.
49. Andoh, A., et al., Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol, 2011. 46(4): p. 479-86.
50. Yang, C., et al., Fecal IgA Levels Are Determined by Strain-Level Differences in Bacteroides ovatus and Are Modifiable by Gut Microbiota Manipulation. Cell Host Microbe, 2020. 27(3): p. 467-475.e6.
51. Fyderek, K., et al., Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol, 2009. 15(42): p. 5287-94.
52. Walujkar, S.A., et al., Molecular profiling of mucosal tissue associated microbiota in patients manifesting acute exacerbations and remission stage of ulcerative colitis. World J Microbiol Biotechnol, 2018. 34(6): p. 76.
53. Machiels, K., et al., A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut, 2014. 63(8): p. 1275-83.
54. Tyler, A.D., et al., Characterization of the gut-associated microbiome in inflammatory pouch complications following ileal pouch-anal anastomosis. PLoS One, 2013. 8(9): p. e66934.
55. Pascal, V., et al., A microbial signature for Crohn's disease. Gut, 2017. 66(5): p. 813-822.
56. Kump, P., et al., The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther, 2018. 47(1): p. 67-77.
57. Rajilić-Stojanović, M., et al., Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis, 2013. 19(3): p. 481-8.
58. Fuentes, S., et al., Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. Isme j, 2017. 11(8): p. 1877-1889.
59. Paramsothy, S., et al., Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis, 2017. 11(10): p. 1180- 1199.
60. Xu, J., et al., 5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. Front Microbiol, 2018. 9: p. 1274.
論文の公開元へ
